Clinical Trials Logo

Metastatic NSCLC clinical trials

View clinical trials related to Metastatic NSCLC.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03417882 Terminated - Metastatic NSCLC Clinical Trials

GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC

Start date: January 3, 2019
Phase: Phase 2
Study type: Interventional

This is a non-randomized, Phase 2, 2-stage, open-label, multi-center study of GRN-1201/sargramostim + pembrolizumab in subjects with PD-L1+ metastatic NSCLC. All subjects will have newly diagnosed metastatic PD-L1+ (TPS ≥ 50%) NSCLC with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. Subjects with EGFR or ALK genomic tumor aberrations with progression on FDA-approved therapy for these aberrations are eligible